The Molecular Immunology Of Tolerance
耐受性的分子免疫学
基本信息
- 批准号:6672772
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:CD28 molecule T lymphocyte autoimmunity chemical stability gene induction /repression homologous transplantation human tissue immune tolerance /unresponsiveness immunogenetics inflammation interleukin 2 leukocyte activation /transformation messenger RNA nervous system transplantation posttranscriptional RNA processing
项目摘要
The mission of the Clinical and Molecular Immunology Group within the Clinical Immunology Section is to perform cellular, molecular and clinical studies aimed at understanding the basis of immune tolerance. A long-term objective is to develop new therapies for allograft transplantation and the treatment of autoimmune and inflammatory diseases.
I. CD28 Signaling
Signaling through the CD28 receptor during T cell activation exerts a profound influence on the outcome of T cell receptor (TCR) engagement. Failure to receive a costimulatory signal through CD28 results in an unresponsive state termed anergy or in T cell death; both of which contribute to the induction and maintenance of immune tolerance. Thus CD28 signaling is a critical determinant of T cell activation and is an important factor in the development of both auto- and allo- immunity. While signal transduction through the T cell receptor has been extensively characterized, the CD28 signaling pathway is poorly understood. To decipher this pathway, we've utilized a mouse model system in which CD28 signaling is responsible for greater than 99% of T cell IL-2 production. Earlier work had shown that this CD28 dependent regulation of IL-2 expression is not at the transcriptional or translational levels but rather a consequence of increased IL-2 mRNA stability.
Our earlier work using sequence tagged genomic IL-2 reporter constructs demonstrated that sequences within the 3' untranslated region of the mouse IL-2 mRNA are responsible for mRNA instability but cannot confer CD28 responsiveness upon a heterologous reporter mRNA. In addition, we discovered the presence of an additional mRNA instability element located within exon 3 and that sequences within exon 2 and the coding region of exon 4 are required for CD28 mediated IL-2 mRNA stabilization. Within these same regions of the IL-2 mRNA we have identified a sequence motif that may be critical for CD28 responsiveness. To test the role of this putative CD28 response element (RE) nearly a dozen mutants have been generated and stable cell lines carrying these mutations have been established. Unexpectedly, analyses of these constructs indicate that CD28 mediated stabilization of the IL-2 mRNA in the cytoplasm appears to be coupled to splicing of the pre-mRNA in the nucleus. While this finding has complicated our studies on the role of the exonic CD28RE?s, we are actively pursuing this novel finding to determine how and why these two processes are coupled. The results of these studies will assist us in the identification of RNA binding proteins that interact with cytokine mRNAs in a CD28 specific fashion, thus providing us with a protein probe to help elucidate the CD28 signal transduction pathway.
Biochemical studies carried out to identify proteins that bind the IL-2 mRNA initially focused on the 3'UTR of the mRNA. We identified one such protein to be HuR, the mammalian homolog of the Drosophila ELAV (embryonic lethal abnormal vision) gene. It is widely held that HuR binding stabilizes labile mRNAs such as c-myc and IL-3, however, we found no association between HuR binding to the IL-2 mRNA and its CD28-mediated stabilization. The controversial nature of our observation has prompted us to determine the biological significance of this finding. One hypothesis that is being pursued is that such binding is related to transport of the mRNA from the nucleus to the cytoplasm. This proposal is supported by our observation that HuR appears to translocate from the nucleus to the cytoplasm upon T cell activation. In addition to furthering our elucidation of the CD28 costimulatory pathway, these observations may have important consequences for our understanding of how IL-2 gene expression is regulated at both the transcriptional and post-transcriptional levels. The initial results of these studies have been submitted for publication.
II. Molecular Consequences of IL-2 Receptor Blockade
Laboratory investigations to understand the mechanism(s) by which blockade of CD25, the high affinity IL-2 receptor (a therapeutic modality in transplantation, allergic, and autoimmune disease) inhibits immune activation have completed their initial phase of study. We found that receptor blockade inhibits the expression of multiple cytokines (both Th1 and Th2) implicated in the pathogenesis of autoimmune disease and graft rejection. We have gone on to show that inhibition of IFN-gamma production occurs through both IL-12 dependent and IL-12 independent pathways. Furthermore, inhibition via the IL-12 dependent pathway is a consequence of blocking CD40L expression, which itself is critical for the induction of IL-12 from monocytes. Furthermore, our results reveal for the first time that both IFN-gamma production and CD40L expression are biphasic and that the latter, but not the initial phase of expression, is highly dependent of IL-2R signaling. These findings, which recently appeared in press, have important implications for the choice of immunosuppressive regimen (e.g. anti- IL-2R vs. anti- IL-12) employed in the setting of transplantation or autoimmune disease. These observations will be extended to understand at the molecular level the activation pathways involved in CD40L expression. Others have showed that blocking CD40L alone can induce long-term tolerance in a primate transplant model. As this has never been accomplished by blocking any other molecule, it will be of critical importance to understand the pathways controlling the expression of this important determinant of immune tolerance.
Recently, a great deal of scientific interest has focused on a subpopulation of CD4 T cells that are characterized in part by expressing CD25 on their surface. These resting cells, in contradistinction to activated CD25+ CD4 T cells, appear in the mouse to play an important role in the homeostasis of the immune system and in establishing tolerance. An analogous population has been defined in humans but their in vivo significance is unknown. We have a patient population that has been treated with a monoclonal antibody against CD25 for over 4 years, but contrary to what might have been predicted from the mouse experiments, these patients are healthy; showing no evidence of immune dysregulation. This patient population presents a unique opportunity to study the functional significance of these CD4/CD25+ regulatory cells in humans. We have begun to do so by further characterizing these cells in normal blood donors in an attempt to better define this population phenotypically.
III. Oral Tolerance
Our earlier results suggested that oral administration of a human IRBP DNA vaccine slightly reduced the experimental autoimmune uveitis induced in mice by the human protein antigen administered with a very powerful adjuvant. Due to the marginal effects that were observed, this project will remain inactive until more robust approaches have been developed.
临床免疫学部分中临床和分子免疫学组的使命是进行细胞,分子和临床研究,以了解免疫耐受性的基础。一个长期目标是开发新疗法,用于同种异体移植以及自身免疫性和炎症性疾病的治疗。
I. CD28信号
T细胞活化过程中通过CD28受体的信号传导对T细胞受体(TCR)参与的结果产生了深远的影响。未能通过CD28接收共刺激信号会导致无反应状态被称为Anergy或T细胞死亡;两者都有助于免疫耐受性的诱导和维持。因此,CD28信号传导是T细胞激活的关键决定因素,并且是自动免疫和同种免疫力发展的重要因素。尽管通过T细胞受体的信号转导已广泛表征,但CD28信号通路的理解很少。为了破译这一途径,我们使用了一个小鼠模型系统,其中CD28信号传导造成了T细胞IL-2产生的99%以上。较早的工作表明,IL-2表达的CD28依赖性调节不是在转录或翻译水平上,而是IL-2 mRNA稳定性增加的结果。
我们使用序列标记的基因组IL-2报告基因构建体的较早工作表明,小鼠IL-2 mRNA的3'未翻译区域内的序列负责mRNA的不稳定性,但不能在异源记者mRNA上赋予CD28响应性。此外,我们发现了位于外显子3中的附加mRNA不稳定性元件的存在,并且外显子2中的序列和外显子4的编码区域是CD28介导的IL-2 mRNA稳定所必需的。在IL-2 mRNA的这些相同区域中,我们确定了一个序列基序,这对于CD28响应性至关重要。为了测试该推定的CD28响应元件(RE)的作用,已经产生了几乎十二个突变体,并建立了携带这些突变的稳定细胞系。出乎意料的是,对这些构建体的分析表明,CD28介导的IL-2 mRNA在细胞质中的稳定似乎与核中MRNA的剪接耦合。尽管这一发现使我们对外显子CD28RE的作用的研究变得复杂,但我们正在积极追求这一新颖的发现,以确定这两个过程是如何以及为什么耦合的。这些研究的结果将有助于我们以CD28特异性方式鉴定与细胞因子mRNA相互作用的RNA结合蛋白,从而为我们提供蛋白质探针,以帮助阐明CD28信号转导途径。
进行的生化研究是为了鉴定结合最初集中在mRNA 3'UTR的IL-2 mRNA的蛋白质。我们确定了一种这样的蛋白质是HUR,是果蝇Elav(胚胎致死异常视力)基因的哺乳动物同源物。人们普遍认为,HUR结合可以稳定不稳定的mRNA,例如C-MYC和IL-3,但是,我们发现HUR与IL-2 mRNA与IL-2 mRNA的结合与其CD28介导的稳定性之间没有关联。我们观察的有争议的性质促使我们确定了这一发现的生物学意义。一种被提出的假设是,这种结合与mRNA从细胞核到细胞质的转运有关。我们的观察结果支持了这一建议,即在T细胞激活时,HUR似乎从细胞核转移到细胞质。除了进一步阐明CD28共刺激途径外,这些观察结果可能对我们对如何在转录和转录后水平调节IL-2基因表达的理解产生重要的影响。这些研究的最初结果已提交出版。
ii。 IL-2受体阻滞的分子后果
实验室研究以了解阻断CD25,高亲和力IL-2受体(移植,过敏和自身免疫性疾病的治疗方式)的机制的机制。我们发现受体阻滞抑制了与自身免疫性疾病和移植排斥的发病机理有关的多种细胞因子(TH1和TH2)的表达。我们继续表明,通过IL-12依赖性和IL-12独立途径,对IFN-gamma产生的抑制作用发生。此外,通过IL-12依赖途径抑制是阻断CD40L表达的结果,这本身对于从单核细胞诱导IL-12至关重要。此外,我们的结果首次揭示了IFN-GAMMA的产生和CD40L表达都是双相的,而后者(但不是表达的初始阶段)高度依赖于IL-2R信号传导。这些最近出现在印刷中的发现对在移植或自身免疫性疾病的情况下采用的免疫抑制方案(例如抗IL-2R与抗IL-12)具有重要意义。这些观察结果将扩展到在分子水平上了解CD40L表达中涉及的激活途径。其他人则表明,仅阻止CD40L可以在灵长类动物移植模型中诱导长期耐受性。由于从未通过阻止任何其他分子来实现这一目标,因此了解控制这种免疫耐受性决定因素的表达的途径至关重要。
最近,很大一部分科学的兴趣集中在CD4 T细胞的亚群上,这些细胞的一部分是通过表面表达CD25来表征的。这些静止的细胞与活化的CD25+ CD4 T细胞相反,在小鼠中出现,在免疫系统的体内稳态中起着重要作用并在建立耐受性中起着重要作用。人类已经定义了类似的人群,但它们的体内意义尚不清楚。我们有一个患者人群已接受针对CD25的单克隆抗体治疗已有4年以上,但与从小鼠实验中预测的情况相反,这些患者是健康的。没有显示免疫失调的证据。该患者人群为研究人类这些CD4/CD25+调节细胞的功能意义提供了独特的机会。我们已经开始通过进一步表征正常献血者中的这些细胞来做到这一点,以便更好地在表型上定义这一人群。
iii。口服耐受性
我们的早期结果表明,口服人IRBP DNA疫苗略微降低了用非常强大的佐剂施用的人蛋白抗原引起的小鼠诱导的实验性自身免疫性葡萄膜炎。由于观察到的边际效应,该项目将保持不活跃,直到开发出更健壮的方法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jack Ragheb其他文献
Jack Ragheb的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jack Ragheb', 18)}}的其他基金
Molecular Biology--Experimental/Clinical Immune Toleranc
分子生物学--实验/临床免疫耐受
- 批准号:
7139197 - 财政年份:
- 资助金额:
-- - 项目类别:
The Molecular Biology Of Experimental and Clinical Immune Tolerance
实验和临床免疫耐受的分子生物学
- 批准号:
7594067 - 财政年份:
- 资助金额:
-- - 项目类别:
The Molecular Biology Of Experimental and Clinical Immune Tolerance
实验和临床免疫耐受的分子生物学
- 批准号:
7734612 - 财政年份:
- 资助金额:
-- - 项目类别:
相似国自然基金
mtDNA介导的cGAS-STING信号通路通过调控自噬参与自身免疫性甲状腺炎的机制研究
- 批准号:81900713
- 批准年份:2019
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
滤泡辅助性T细胞在CTLA-4Ig诱导Graves病免疫耐受中的作用及机制研究
- 批准号:81801621
- 批准年份:2018
- 资助金额:21.0 万元
- 项目类别:青年科学基金项目
MDSCs在自身免疫性葡萄膜炎中的作用及机制研究
- 批准号:81800815
- 批准年份:2018
- 资助金额:21.0 万元
- 项目类别:青年科学基金项目
TRPV4通道调节T细胞分化介导自身免疫性心肌炎的发病机制研究
- 批准号:81700332
- 批准年份:2017
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
铁离子参与自身免疫性疾病中促炎性细胞因子的转录后调控机制研究
- 批准号:81671552
- 批准年份:2016
- 资助金额:57.0 万元
- 项目类别:面上项目
相似海外基金
Development of a cellular therapy product with single specificity and improved persistence to prevent immunity to biotherapeutics
开发具有单一特异性和改善持久性的细胞治疗产品,以防止对生物治疗药物的免疫
- 批准号:
10726703 - 财政年份:2023
- 资助金额:
-- - 项目类别:
System Dynamics of PD-1 Signaling in T Cells
T 细胞中 PD-1 信号传导的系统动力学
- 批准号:
10399590 - 财政年份:2021
- 资助金额:
-- - 项目类别:
System Dynamics of PD-1 Signaling in T Cells
T 细胞中 PD-1 信号传导的系统动力学
- 批准号:
10211871 - 财政年份:2021
- 资助金额:
-- - 项目类别:
Investigating the interplay of structural, molecular and spatial mechanisms that control SHP2 activity downstream of PD1
研究控制 PD1 下游 SHP2 活性的结构、分子和空间机制的相互作用
- 批准号:
9769062 - 财政年份:2018
- 资助金额:
-- - 项目类别:
Investigating the interplay of structural, molecular and spatial mechanisms that control SHP2 activity downstream of PD1
研究控制 PD1 下游 SHP2 活性的结构、分子和空间机制的相互作用
- 批准号:
10002277 - 财政年份:2018
- 资助金额:
-- - 项目类别: